Sagimet Biosciences Inc. Files Current Report
Ticker: SGMT · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1400118
Sentiment: neutral
Topics: current-report, sec-filing, public-company
Related Tickers: SGMT
TL;DR
SGMT filed an 8-K on 2/14/25, confirming its Nasdaq listing.
AI Summary
Sagimet Biosciences Inc. reported on February 14, 2025, that its Series A Common Stock trades under the symbol SGMT on The Nasdaq Global Market. The company, incorporated in Delaware, is headquartered in San Mateo, California. This filing is a routine current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing confirms Sagimet Biosciences Inc.'s status as a publicly traded company on Nasdaq under the ticker SGMT, providing essential information for investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a standard current report and does not contain new material information that would inherently increase risk.
Key Numbers
- 001-41742 — Commission File Number (Identifies the company's filing with the SEC)
- 20-5991472 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- February 14, 2025 (date) — Date of earliest event reported
- SGMT (stock_symbol) — Trade Symbol for Series A Common Stock
- The Nasdaq Global Market (exchange) — Name of exchange where Series A Common Stock is registered
- Delaware (jurisdiction) — State of incorporation
- San Mateo, California (location) — Address of principal executive offices
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose is to report current information as required by Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest reported event date being February 14, 2025.
What is the trading symbol for Sagimet Biosciences Inc.'s Series A Common Stock?
The trading symbol for Sagimet Biosciences Inc.'s Series A Common Stock is SGMT.
On which exchange is Sagimet Biosciences Inc.'s Series A Common Stock registered?
Sagimet Biosciences Inc.'s Series A Common Stock is registered on The Nasdaq Global Market.
Where is Sagimet Biosciences Inc. headquartered?
Sagimet Biosciences Inc. is headquartered at 155 Bovet Road, Suite 303, San Mateo, California 94402.
Is Sagimet Biosciences Inc. an emerging growth company?
Yes, the filing indicates by check mark that Sagimet Biosciences Inc. is an emerging growth company.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-02-14 16:15:26
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm256733d1_8k.htm (8-K) — 26KB
- tm256733d1_ex99-1.htm (EX-99.1) — 48KB
- tm256733d1_ex99-1img001.jpg (GRAPHIC) — 159KB
- tm256733d1_ex99-1img002.jpg (GRAPHIC) — 405KB
- tm256733d1_ex99-1img003.jpg (GRAPHIC) — 188KB
- tm256733d1_ex99-1img004.jpg (GRAPHIC) — 212KB
- tm256733d1_ex99-1img005.jpg (GRAPHIC) — 153KB
- tm256733d1_ex99-1img006.jpg (GRAPHIC) — 126KB
- tm256733d1_ex99-1img007.jpg (GRAPHIC) — 152KB
- tm256733d1_ex99-1img008.jpg (GRAPHIC) — 133KB
- tm256733d1_ex99-1img009.jpg (GRAPHIC) — 153KB
- tm256733d1_ex99-1img010.jpg (GRAPHIC) — 84KB
- tm256733d1_ex99-1img011.jpg (GRAPHIC) — 162KB
- tm256733d1_ex99-1img012.jpg (GRAPHIC) — 160KB
- tm256733d1_ex99-1img013.jpg (GRAPHIC) — 119KB
- tm256733d1_ex99-1img014.jpg (GRAPHIC) — 108KB
- tm256733d1_ex99-1img015.jpg (GRAPHIC) — 143KB
- tm256733d1_ex99-1img016.jpg (GRAPHIC) — 183KB
- tm256733d1_ex99-1img017.jpg (GRAPHIC) — 115KB
- tm256733d1_ex99-1img018.jpg (GRAPHIC) — 170KB
- tm256733d1_ex99-1img019.jpg (GRAPHIC) — 122KB
- tm256733d1_ex99-1img020.jpg (GRAPHIC) — 112KB
- tm256733d1_ex99-1img021.jpg (GRAPHIC) — 125KB
- tm256733d1_ex99-1img022.jpg (GRAPHIC) — 112KB
- tm256733d1_ex99-1img023.jpg (GRAPHIC) — 153KB
- tm256733d1_ex99-1img024.jpg (GRAPHIC) — 169KB
- tm256733d1_ex99-1img025.jpg (GRAPHIC) — 189KB
- tm256733d1_ex99-1img026.jpg (GRAPHIC) — 173KB
- tm256733d1_ex99-1img027.jpg (GRAPHIC) — 182KB
- tm256733d1_ex99-1img028.jpg (GRAPHIC) — 84KB
- tm256733d1_ex99-1img029.jpg (GRAPHIC) — 89KB
- tm256733d1_ex99-1img030.jpg (GRAPHIC) — 156KB
- tm256733d1_ex99-1img031.jpg (GRAPHIC) — 206KB
- tm256733d1_ex99-1img032.jpg (GRAPHIC) — 155KB
- tm256733d1_ex99-1img033.jpg (GRAPHIC) — 158KB
- tm256733d1_ex99-1img034.jpg (GRAPHIC) — 189KB
- tm256733d1_ex99-1img035.jpg (GRAPHIC) — 144KB
- tm256733d1_ex99-1img036.jpg (GRAPHIC) — 228KB
- 0001104659-25-014099.txt ( ) — 8031KB
- sgmt-20250214.xsd (EX-101.SCH) — 3KB
- sgmt-20250214_lab.xml (EX-101.LAB) — 33KB
- sgmt-20250214_pre.xml (EX-101.PRE) — 22KB
- tm256733d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On February 14, 2025, Sagimet Biosciences Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated February 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: February 14 , 2025 By: /s/ David Happel David Happel Chief Executive Officer